May 2025

Week in Review: Boston Scientific pulls plug on TAVR devices | Edibles do harm | Lead-free cath labs | A key approval for Abbott ()
FDA wants more warnings on COVID vaccines | Many heart failure patients still not seeking care | Cannabis linked to new risks ()
What private equity means for patients | Pioneers of pediatric cardiology | Gastrointestinal bleeding after TAVR ()
Patient's family sues health system for negligence | Cardiologist accused of abuse | Woman says husband was misdiagnosed ()
Boston Scientific pulls plug on TAVR devices | Trends in cardiac surgery | Marijuana bad for blood vessels | Cuffless BP tech ()
Employment models keep evolving | J&J MedTech ordered to pay $147M | Boston Scientific pulls plug on TAVR devices ()
Breaking News: Boston Scientific pulls plug on TAVR devices ()
Wait times to see a cardiologist keep increasing | FDA approves Abbott's TMVR device | PPMI after mitral valve surgery ()
TTVR tech used for first time | SCAI wants lead-free cath labs | A big day for Medtronic DCB | Meril TAVR valves after 1 year ()
Jury orders J&J MedTech to pay $147M | Cooling device terminates AFib | The risks of cannabis use | PFA linked to heart damage ()
Week in Review: J&J MedTech ordered to pay $147M | Changing employment models | FDA wants new heart warnings on COVID vaccines ()
Devices recalled after FDA raises concerns | AI delivers real-time blood clot monitoring | The evolution of stroke care ()
World's first use of robotic imaging system | FDA wants more heart warnings on COVID vaccines | AVR in asymptomatic patients ()
Medtronic to spin off diabetes business | Stroke care keeps evolving | A key TAVR valve approval | J&J MedTech's new catheter ()
Champagne may be good for the heart | Tirzepatide bests semaglutide | The risks of consistent cannabis use ()
Same-day discharge after TAVR | IVL & women | Chest tube-clearing device boosts outcomes after surgery ()
PFA linked to heart damage | Cooling device terminates AFib | A close look at CT-guided PCI | Same-day discharge after ablation ()
J&J MedTech ordered to pay $147M for antitrust violations | Skipping the cardiologist | Active patients live longer ()
Changes in cardiologist employment | Robotic PCI is safe & effective | Banksy auction will fund research | AI tracks blood clots ()
Week in Review: When TAVR valves fail | A new use for IVL | Semaglutide works fast | Obicetrapib in high-risk patients ()
Comparing intra-annular TAVR valves | Abbott's FreeStyle Libre makes an impact | Imaging & chest pain | The benefits of Barostim ()
Cardiology groups speak up | Seeking answers after the FDA approved TAVR for asymptomatic AS | SDD after cardiac ablation ()
Key details about PCI after TAVR | Cardiology groups oppose Medicaid cuts | Semaglutide works fast | Reframing leadership myths ()
Surgery, not TAVR, still preferred for some patients | Drug helps surgeons avoid a 'bloody mess' | Robotic mitral valve repair ()
FDA impressed by AI-powered blood test | Comparing TAVR valves | A big approval for GE HealthCare | New HCM drug delivers ()
Radiation protection in the cath lab | Imaging catheters removed from market over safety risks | CT-guided PCI ()
When TAVR valves fail | Cardiology groups share a tariff warning | Bariatric surgery & the heart | GE HealthCare debuts MRI tech ()
Tricuspid outcomes keep improving | BATMAN helps cardiologists | IVL & TAVR | Robotic mitral valve repair ()
A new use for IVL | TAVR & SAVR in patients with low-flow, low-gradient AS | Obicetrapib linked to substantial LDL-C reductions ()
Week in Review: Tirzepatide bests semaglutide | TAVR approved for asymptomatic patients | BATMAN limits complications ()
Highlights from SCAI 2025: Meet the new president | Tirzepatide vs. semaglutide | Cannabis & heart failure | CT-guided PCI ()
New cooling device used for first time to terminate AFib | CCTA shows colchicine's impact | Heart health in US getting worse ()
Key questions after FDA approval of TAVR in asymptomatic patients | High Lp(a) levels raise risk of repeat cardiovascular events ()
Terminating AFib for good | The evolution of AI in cardiology | Predicting LBBB risk after TAVR | Key FDA approvals ()
Promising outcomes for world's first leadless LBBAP procedures | Elevated risks for some heart pump patients | Stents & CTO PCI ()
April's Top Stories: Medical device recalls | Patient's family awarded $45M | TAVR valve used for first time | FDA's new warning ()
SCAI's new president outlines his goals | Tirzepatide wins battle of the diabetes drugs | AI predicts LBBB risk in TAVR patients ()
Getting the most out of CT-guided PCI | Cannabis use & heart failure | Helping startups push forward | New BATMAN data ()
Week in Review: FDA approves TAVR for asymptomatic patients | Heart pump accessories recalled | PFA linked to heart damage risk ()
FDA approves TAVR for asymptomatic patients | Should guidelines be updated? | AI-enabled WCD gains approval | SCAI 2025 ()
Breaking News: FDA approves first TAVR valves for asymptomatic severe aortic stenosis ()
Heart damage after PFA | Radiotherapy protects the hearts of breast cancer patients | New tech improves transplant outcomes ()